@文章{Stek1901692，作者= {Stek, Cari和Allwood, Brian和Du Bruyn, Elsa和Buyze, Jozefien和Schutz, Charlotte和Thienemann, Friedrich和Lombard, Adele和Wilkinson, Robert J.和Meintjes, Graeme和Lynen, Lutgarde}，标题= {hiv相关结核病，结核病- iris，和强尼松对肺功能的影响}，位置-id ={1901692}，年份= {2019}，doi ={10.1183/13993003.01692-2019}，出版商={欧洲呼吸学会}，188bet官网地址肺结核治疗后残留的肺损伤很常见。艾滋病毒相关结核病患者的肺功能数据很少，特别是在自相矛盾的结核病相关免疫重建炎症综合征(TB-IRIS)和预防性强的松的背景下。我们的目的是确定hiv相关结核病患者肺功能异常的患病率和CD4计数<=100 cells{\ textperiodcentric}μL-1，并评估预防性强的松和非特异性TB-IRIS的发展对肺损害的影响。我们对PredART试验的参与者在基线(第0周)、第4周、第12周和第28周进行了肺活量测定、6分钟步行试验和胸部x线摄影，该试验评估了开始抗逆转录病毒治疗的hiv相关结核病患者使用泼尼松预防TB-IRIS的28天疗程。153名参与者在一个或多个时间点进行了肺活量测量和/或6分钟步行测试。在第0周，66\%的参与者和第28周50\%的参与者出现了异常的肺活量测量;强迫肺活量低是最常见的异常。胸部x光片显示大多数参与者很少或没有异常。使用强的松导致6分钟步行距离增加42米，在第4周1 s内预测用力呼气量提高4.9% \%;从第12周开始，这些差异不再显著不同。 TB-IRIS did not significantly impair lung function outcome.Residual pulmonary impairment is common in HIV-associated tuberculosis. In patients with low CD4 counts, neither prophylactic prednisone as used in our study nor the development of TB-IRIS significantly affected week 28 pulmonary outcome.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Stek has nothing to disclose.Conflict of interest: Dr. Allwood has nothing to disclose.Conflict of interest: Dr. Du Bruyn has nothing to disclose.Conflict of interest: Dr. Buyze has nothing to disclose.Conflict of interest: Dr. Schutz has nothing to disclose.Conflict of interest: Dr. Thienemann has nothing to disclose.Conflict of interest: Dr. Lombard has nothing to disclose.Conflict of interest: Dr. Wilkinson reports grants from Wellcome, grants from UK research and Innovation, grants from National Institutes of Health, grants from Foundation for the National Institues of Health, grants from European and Developing Countries Clinical Trials Partnership, during the conduct of the study.Conflict of interest: Dr. Meintjes has nothing to disclose.Conflict of interest: Dr. Lynen has nothing to disclose.}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/early/2019/12/04/13993003.01692-2019}, eprint = {//www.qdcxjkg.com/content/early/2019/12/04/13993003.01692-2019.full.pdf}, journal = {European Respiratory Journal} }